Drug Approval | October 26, 2021
Glenmark launches novel fixed-dose combination for diabetes
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
Following the pre-NDA meeting with the U.S. FDA, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
The start-up claims in clinical trials over 90 % achieved type 2 diabetes reversal and 92 % eliminated all diabetes medication within 90 days of joining the twin service
More than 90,000 patients utilise the services daily
Cobas pure provides clinical labs with access to more than 230 diagnostic tests across a wide range of disease areas including infectious diseases, oncology and cardiology
Chericof 12, the first prescription cough syrup in India which gives relief for up to 12 hours, is manufactured using Polistirex technology for sustained release of the drug
The company operates in over eight cities and the start-up plans to expand its reach to over 100 non-metro cities in the next 18-24 months
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
Subscribe To Our Newsletter & Stay Updated
